Azeddine Dellal

10 Rue Du Général Leclerc
Montfermeil, 93370, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Sex Differences in Treatment Expectations, Satisfaction and Tolerance After Switching to CT-P17, an Adalimumab Biosimilar: A Post Hoc Analysis of the YU-MATTER Study.

Sex Differences in Treatment Expectations, Satisfaction and Tolerance After Switching to CT-P17, an Adalimumab Biosimilar: A Post Hoc Analysis of the YU-MATTER Study.

Journal: Rheumatology and therapy

Published: January 23, 2026

AA amyloidosis in inflammatory joint diseases in the era of biological therapies: Prevalence, manifestations, management and evolution.

AA amyloidosis in inflammatory joint diseases in the era of biological therapies: Prevalence, manifestations, management and evolution.

Journal: Joint bone spine

Published: January 22, 2026

Salvage therapy with JAK inhibitors in refractory Takayasu arteritis: a multicentre experience.

Salvage therapy with JAK inhibitors in refractory Takayasu arteritis: a multicentre experience.

Journal: RMD open

Published: December 19, 2025

Prognosis and Long-Term Outcome of Stenotic Large Vessel Involvement in Giant Cell Arteritis.

Prognosis and Long-Term Outcome of Stenotic Large Vessel Involvement in Giant Cell Arteritis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: October 20, 2025

Cardiovascular risk among Giant cells arteritis patients.

Cardiovascular risk among Giant cells arteritis patients.

Journal: European journal of preventive cardiology

Published: October 03, 2025

Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: a multicentre retrospective study.

Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: a multicentre retrospective study.

Journal: Rheumatology (Oxford, England)

Published: October 28, 2024

Infliximab versus Cyclophosphamide for Severe Behçet's Syndrome.

Infliximab versus Cyclophosphamide for Severe Behçet's Syndrome.

Journal: NEJM evidence

Published: October 22, 2024

Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study.

Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: September 03, 2024

Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis.

Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis.

Journal: RMD open

Published: June 26, 2024

Trabecular bone score (TBS) in Cushing's disease: TBS gain after hypercortisolism normalization.

Trabecular bone score (TBS) in Cushing's disease: TBS gain after hypercortisolism normalization.

Journal: Bone

Published: January 19, 2024

Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study.

Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study.

Journal: RMD open

Published: October 30, 2022

Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.

Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.

Journal: Joint bone spine

Published: August 24, 2022

Showing 1-12 of 30

Last Updated: 09/26/2026